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Background: Analysis of cerebrospinal fluid (CSF) is a frequently used diagnostic
tool in a variety of neurological diseases. Recent studies suggested that investigating
membrane particles enriched with the stem cell marker CD133 may offer new avenues
for studying neurological disease. In this study, we evaluated the amount of membrane
particle-associated CD133 in human CSF in neuroinflammatory and degenerative
diseases.
Methods: We compared the amount of membrane particle-associated CD133 in CSF
samples collected from 45 patients with normal pressure hydrocephalus, parkinsonism,
dementia, and cognitive impairment, chronic inflammatory diseases and 10 healthy
adult individuals as controls. After ultracentrifugation of CSF, gel electrophoresis and
immunoblotting using anti-CD133 monoclonal antibody 80B258 were performed.
Antigen-antibody complexes were detected using chemiluminescence.
Results: The amount of membrane particle-associated CD133 was significantly
increased in patients with normal pressure hydrocephalus (p < 0.001), parkinsonism
(p = 0.011) as well as in patients with chronic inflammatory disease (p = 0.008).
Analysis of CSF of patients with dementia and cognitive impairment revealed no
significant change compared with healthy individuals. Furthermore, subgroup analysis of
patients with chronic inflammatory diseases demonstrated significantly elevated levels
in individuals with relapsing-remitting multiple sclerosis (p = 0.023) and secondary
progressive multiple sclerosis (SPMS; p = 0.010).
Conclusion: Collectively, our study revealed elevated levels of membrane particle-
associated CD133 in patients with normal pressure hydrocephalus, parkinsonism as
well as relapsing-remitting and SPMS. Membrane glycoprotein CD133 may be of clinical
value for several neurological diseases.
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INTRODUCTION
The cerebrospinal fluid (CSF) is frequently analyzed for
diagnosing a variety of neurological diseases. The basic CSF-
analysis includes cell count, cytological findings and total amount
of protein (Johanson et al., 2011). Specific clinical CSF-analyses
focus on protein-based alterations such as oligoclonal banding,
particular antibodies, or particular soluble proteins such as tau
(Hühmer et al., 2006). Yet, CSF may have a far greater diagnostic
potential considering recent studies demonstrating that CSF
contains small membrane particles (Huttner et al., 2008, 2012;
Colombo et al., 2012; Chiasserini et al., 2014).
As previously shown, CSF-associated membrane particles
may contain CD133, a cholesterol-binding pentaspan membrane
glycoprotein (Figure 1). Although the biological function of this
glycoprotein remains to be demonstrated, it gained attention in
the past few years. CD133 labels stem and progenitor cells in
various organs notably in the neural and hematopoietic system
(Miraglia et al., 1997; Weigmann et al., 1997; Jászai et al., 2013;
Walker et al., 2013; Pruszak, 2015). CD133 highlights cancer
stem cells and marks potential facultative stem cells, which might
be activated during regeneration (Grosse-Gehling et al., 2013;
Corbeil et al., 2014). Besides its expression in progenitor cells,
CD133 is detected in differentiated cells such as epithelial and
glial cells (Karbanová et al., 2008; Corbeil et al., 2009). In the
adult brain it is expressed on multiciliated ependymal cells and
subventricular zone astrocytes. Therein, CD133 is concentrated
in ependymal cilia as well as in primary cilia of quiescent neural
stem cells that are exposed to CSF (Dubreuil et al., 2007; Coskun
et al., 2008; Huttner et al., 2008; Codega et al., 2014; Karbanová
et al., 2014; Nogueira et al., 2014). CD133 is also detected in
myelin sheaths of oligodendrocytes and Schwann cells found
FIGURE 1 | Membrane topology of CD133 and location of the 80B258
epitope. CD133 consists of an extracellular N-terminal domain,
5-transmembrane domains separating two large glycosylated extracellular
loops and two small intracellular loops, and an intracellular C-terminal domain.
Potential N-glycosylation sites are indicated with forks. Mouse-mAb 80B258
was generated against a fusion protein containing part of the first extracellular
loop (residue glycine 240 to serine 388, gray segment) of human prominin-1
(Karbanová et al., 2008).
in central and peripheral nervous system, respectively (Corbeil
et al., 2009). A remarkable biological feature of CD133 is its
release in several body fluids in association with membrane
particles, initially referred to as “prominosomes” (Marzesco et al.,
2005). Thus, CD133 can be recovered upon ultracentrifugation
in urine, tear, saliva, seminal fluid and CSF (Marzesco et al.,
2005; Huttner et al., 2008, 2012; Karbanová et al., 2008, 2014).
Although the release of CD133-associated membrane particles
can occur at a constant rate, particularly in healthy epithelial
cells contacting a given body fluid (e.g., urine, CSF), an increase
of CD133 secretion was linked to the differentiation of stem
and progenitor cells (Marzesco et al., 2005; Dubreuil et al.,
2007; Bauer et al., 2011). The release of CD133 in CSF can
occur by the budding of membrane particles (i.e., ectosomes or
microvesicles) from plasma membrane protrusions (e.g., cilia)
of ependymal cells and/or underlying subventricular astrocytes
(Marzesco et al., 2005; Dubreuil et al., 2007; Corbeil et al.,
2009, 2013; Kriegstein and Alvarez-Buylla, 2009). The release of
CD133 in association with exosomes, i.e., the internal membrane
vesicles of multivesicular bodies that are discharged into the
extracellular space by exocytosis (Fevrier and Raposo, 2004)
cannot be excluded, particularly in cancerous cells. However,
the detection of CD133 in exosomes was reported only with
hematopoietic progenitors (Bauer et al., 2011).
Monitoring the amount of membrane particle-associated
CD133 in body-fluids may provide information about biological
activity of contacting cells and its variation in onset and
progression of several diseases. To date, only two reports were
published on membrane particle-associated CD133 in human
CSF. In essence, these studies found an elevation of CD133 in
early stage glioblastoma as well as in temporal lobe epilepsy
(Huttner et al., 2008, 2012). In the light of such observations,
we investigated the amount of membrane particle-associated
CD133 in CSF of patients with inflammatory and degenerative
neurological diseases and assessed the possible clinical value of
membrane-bound CD133.
MATERIALS AND METHODS
Study Design, Patient Selection and
Retrieval of Clinical Data
The study included patients admitted to the Department
of Neurology, University Hospital Erlangen (Germany)
and was approved by the local institutional review board.
CSF samples were collected in inpatients who received a
diagnostic lumbar puncture, indicated to exclude or verify
neurological disease, and consented for research-based CSF
analysis.
We enrolled (i) 10 patients who received CSF analysis
to exclude subarachnoid hemorrhage or inflammatory disease
showing normal CSF analysis and these patients are in the
following referred to as healthy subjects, (ii) patients with normal
pressure hydrocephalus (n= 6), parkinsonism (n= 6), dementia
and cognitive impairment (n = 8) and chronic inflammatory
central nervous system disease (n = 25). Clinical data and
medical information were collected from our institutional
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database. In patients with chronic inflammatory central nervous
system disease, the Expanded Disability Status Scale (EDSS)
score was assessed during the stay (Kurtzke, 1983), the disease
course was classified as clinical isolated syndrome (CIS) /
relapsing remitting (RR), secondary progressive (SP) or primary
progressive (PP) multiple sclerosis and myelitis (Rovira et al.,
2009; Montalban et al., 2010). For diagnosis of multiple sclerosis,
brain images were acquired. Images were done at a 1.5-T MRI
(Siemens AG, Erlangen, Germany) consisting of an axial T1-
and T2-weighted spin echo sequences. Brain atrophy (Bermel
and Bakshi, 2006) and lesion load measurements were scored as
recently described (Ormerod et al., 1987; Petzold et al., 2016).
Samples of patients with inflammatory diseases were obtained
during patient’s hospitalization for relapse therapy. In patients
with dementia or cognitive impairment, the total tau protein,
phospho-tau and the 42 and 40 amino acid form of amyloid β
were analyzed (Zetterberg, 2015).
Isolation of CD133-Membrane Particles
Upon lumbar puncture, an aliquot (1 ml) from the collected CSF
was frozen at−80◦C immediately after adding protease inhibitor
according to the manufacturer’s instruction (Roche Diagnostics,
Cat. No. 04693116001, Mannheim, Germany). CSF samples (1 ml
each) were thawed on ice and sequentially centrifuged for 30 min
at 10.000 × g at 4◦C, the resulting supernatants were collected
and centrifuged for 1 h at 100.000 × g at 4◦C. Supernatants were
discarded, and 100.000 × g pellets were resuspended in 35 µl
Laemmli buffer and analyzed by immunoblotting (see below)
(Huttner et al., 2008). Extracts from human Caco-2 cells were
used as positive controls and to establish the standard curve
since these cells express CD133 (Corbeil et al., 2000; Marzesco
et al., 2005; Huttner et al., 2008). Caco-2 cells were produced
in a medium with 20% fetal calf serum, 2 mM L-glutamine, 1%
non-essential amino acids, 100 U/ml penicillin, and 100 µg/ml
streptomycin under a 5% CO2 atmosphere at 37◦C. Caco-2
cells were grown until 10 days post-confluence. Cells extracts
were prepared as described (Huttner et al., 2008) and the
protein concentration was measured using BCA Protein Assay
(BCA Protein Assay Kit Pierce, Thermo Fisher, Cat. No. 23252,
Waltham, MA, USA). The Caco-2 cell extract used had a protein
concentration of 10 µg/µl and was diluted 1:100.
Quantitative Immunoblotting
Probes and positive controls were subjected to Tris-Glycine gels
(Precise 8% Tris-Glycine Gels, ThermoFisher, Cat. No. 25260,
Waltham, MA, USA) and transferred to polyvinylidene difluoride
membranes (Immobilon-P membrane, Merck Millipore,
IPVH00010, 0.45 µm, Billerica, MA, USA) as published (Huttner
et al., 2008, 2012). After blocking for 1 h in PBS containing
0.3% Tween-20 and 5% low-fat milk powder (blocking
solution), membranes were incubated for 12 h in blocking
solution containing mouse monoclonal antibody (mAb) 80B258
(1 µg/ml; isotype IgG1) (Karbanová et al., 2008). Membranes
were then washed thrice for 15 min in PBS containing 0.3%
Tween-20 and incubated for 1 h in blocking solution containing
horseradish peroxidase conjugated goat anti-mouse secondary
antibody (1:5000; Jackson Immunoresearch Laboratories,
Cat. No. 115-035-068, West Grove, PA, USA). The antigen-
antibody complexes were detected using Chemiluminescence
reagents (SuperSignal West Femto Substrate, ThermoFisher
Scientific, Cat. No. 34095, Waltham, Massachusetts, USA).
Total transferred proteins were detected using Ponceau staining
(Ponceau S solution, Sigma-Aldrich, Cat. No. P7170, St. Louis,
MO, USA) (Supplementary Figures 1, 2). For visualization
of antigen-antibody complexes, the image reader Fusion FX7
Spectra (Vilber Lourmat GmbH, Eberhardzell, Germany) was
utilized, and quantification was performed using Image Quant TL
(GE Healthcare Europe GmbH, Freiburg, Germany). Absorbance
values within the linear range were used for statistical analysis
as described (Huttner et al., 2012). An internal standard sample
was established using the standard curve derived from Caco-2
cell extract and evaluated on each blot (Supplementary Figure 2).
The absorbance levels of analyzed CSF samples of diseased
individuals were compared to the mean absorbance level of
healthy individuals and expressed as a deviation in percentages
(CD133-deviation).
Statistical Analysis
Data were processed using Office 2013 software package
(Microsoft Corp., Redmond, WA, USA). Statistical analysis was
performed with SPSS statistical software package 21.0 (SPSS
Inc., Chicago, IL, USA). Distribution of the data was established
using the Kolmogorov–Smirnov test. Normal distributed data are
presented as mean± standard deviation (SD) as well as standard
error of the mean (SEM) (compared using Student’s t-test). Other
data are shown as median and interquartile ranges (compared
using Mann–Whitney U-test). Absorbance values of each group
are calculated referring to healthy subjects. A logistic regression
model was used to investigate the relationship between CD133-
deviation and basic CSF analysis as well as EDSS-score and lesion
load. All statistical tests were two-sided with a significance level
of α= 0.05 without adjustment for multiple comparisons.
RESULTS
Detection of CD133-Positive Membrane
Particles in the CSF of Healthy and
Diseased Patients
The amount of membrane particle-associated CD133 in the
CSF of healthy subjects was determined upon differential
centrifugation of CSF followed by semi-quantitative
immunoblotting of the resulting fractions. The CD133
glycoprotein was detected using our characterized mouse
mAb 80B258, which recognized a polypeptide epitope located
in its extracellular loop (Figure 1) (Karbanová et al., 2008). The
blotting was performed by analyzing three defined amounts of a
CD133-containing Caco-2-cell extract (for technical details and
the establishment of standard curve see Materials and Methods,
Supplementary Figures 1, 2). Such controls were used to establish
an internal reference. From 1 ml aliquot of CSF, we recovered
1.319 × 103 ± 682 × 103 pixel/ absorbance units of CD133
immunoreactivity in healthy subjects. This amount was used as a
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reference to healthy subjects to determine the variation of CD133
in CSF of diseased patients.
The characteristics of all included patients with normal
pressure hydrocephalus, Parkinson’s disease, dementia and
cognitive impairment, and chronic inflammatory disease are
summarized in Tables 1, 2. Basic parameters of CSF-analysis
is provided in the Supplementary Table 1. Interestingly, there
was a significant increase of CD133 in CSF collected from six
patients with normal pressure hydrocephalus [261% ± 81.5%
(SD) or 42% (SEM); p< 0.001] and six others with parkinsonism
[230% ± 69% (SD) or 53%; p = 0.011]. In the latter cases,
the increase of CD133 was observed in patients with atypical
parkinsonism [two patients; 357% ± 90% (SD) or 54% (SEM);
p = 0.03], patients with parkinson disease showed only a trend
toward increased CD133 [four patients; 167% ± 60% (SD) or
30% (SEM); p = 0.076]. CSF-associated CD133 levels were also
elevated in eight patients with dementia/cognitive impairment
[190% ± 150% (SD) or 52% (SEM)] but the increase is not
significant by comparison to healthy subjects (p = 0.237).
Lastly, the analysis of 25 patients with chronic inflammatory
diseases revealed an elevated amount of CD133 in their CSF
[321% ± 210% (SD) or 58% (SEM); p = 0.008] (Figure 2).
Regression analysis revealed no association between CD133-
deviation and parameters of basic CSF-analysis (glucose, lactate,
protein) (Figure 3).
Subgroups of Chronic Inflammatory
Disease
Given that patients with chronic inflammatory diseases showed
the highest increase in CSF-associated CD133 (Figure 2),
TABLE 1 | Clinical parameters of healthy subjects, patients with normal
pressure hydrocephalus, parkinsonism, and dementia/cognitive
impairment.
Parameters Values
Healthy subjects (n = 10)
Age (years), median (range) 53 (49.3–61.5)
Sex (female/male) 6/4
Reason for lumbar puncture (n)
Exclusion of subarachnoid hemorrhage 2 (20%)
Exclusion of inflammatory disease 8 (80%)
Normal pressure hydrocephalus (n = 6)
Age (years), median (range) 72 (66–78)
Sex (female/male) 1/5
Parkinson syndrome (n = 6)
Age (years), median (range) 73.0 (68.5–78.5)
Parkinson disease (%) 4 (66.67%)
Atypical parkinsonism (%) 2 (33.34%)
Dementia / cognitive impairment (n = 8)
Age (years), median (range) 70.4 (68.5–75.0)
Sex (female/male) 4/4
ß-Amyloid 1–42 pg/ml (range) 821 (687–1232)
Ratio ß-Amyloid 1–42/1–40 0.037 (0.031–0.251)
Total tau pg/ml (range) 486.5 (358.0–749.5)
Phosphor tau pg/ml (range) 76.3 (48.6–94.0)
TABLE 2 | Clinical parameters of the included patients with chronic
inflammatory disease.
Parameters Values
Subjects with central nervous inflammatory disease (n = 25)
Age (years), median (range) 47.5 (41.25–53.75)
Sex (female/male) (17/8)
CIS / RRMS n (%) 7 (28.0%)
SPMS n (%) 10 (40.0%)
PPMS n (%) 5 (20.0%)
Myelitis n (%) 3 (12.0%)
Current EDSS score median (range) 5.0 (2.0–6.5)
Disease duration (months), median (range) 120 (27–249)
Neuroradiological data (n = 25)
T2 lesions
Periventricular
Lesion 6–10 mm (%) 62.5% (15)
Lesion >10 mm (%) 50.0% (12)
Juxtacortical
Lesion 6–10 mm (%) 66.7% (16)
Lesion >10 mm (%) 25.0% (6)
Infratentorial
Lesion 6–10 mm (%) 29.1% (7)
Lesion >10 mm (%) 16.7% (4)
Score (range) 13.3 (8–21)
Spinal T2 lesions (n = 17) 76.5% (13)
T1 CE lesions
Cerebral lesions 16.7% (4)
Spinal lesions 8.3% (2)
Cerebral atrophy
Bicaudate ratio 0.12 (0.098–0.135)
FIGURE 2 | Variation of membrane particle-associated CD133 in
neurological diseases. Variations of percentage of CD133-deviation in
patients with normal pressure hydrocephalus (NPH), parkinsonism, dementia
and inflammatory diseases by comparison to healthy adults are depicted in
bar graph. Data are mean ± SEM. N.s.: not significant.
we performed a sub-analysis and grouped these 25 patients
into relapsing-remitting multiple sclerosis (RRMS, including
CIS; n = 7), secondary progressive multiple sclerosis (SPMS,
n = 10), primary progressive multiple sclerosis (PPMS,
n = 5) and patients with isolated myelitis (n = 3). Baseline
characteristics, clinical and radiological parameters are shown in
Table 2.
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FIGURE 3 | Logistic regression model between CD133-deviation (%)
and basic CSF-analysis. Logistic regression model comparing
CD133-deviation (%) and Glucose (A; R2 = 0.018; p = 0.312), Lactate (B;
R2 = 0.014; p = 0.365), and Protein (C; R2 = 0.004; p = 0.643). No
correlation is found between these parameters.
Compared to healthy controls, levels of CD133
immunoreactivity in CSF revealed no increase in PPMS and
myelitis-patients [155% ± 90% (SD) or 59% (SEM); p = 0.768;
and 222%± 134% (SD) or 109% (SEM); p= 0.273, see Figure 4].
In contrast, patients with RRMS and SPMS showed increased
CD133-levels compared to healthy controls [291% ± 91% (SD)
or 76% (SEM); p = 0.023], and 434% ± 135% (SD) or 111%
(SEM); p = 0.010, respectively. Finally, further analysis revealed
no correlation between radiological parameters (lesion load / T2
lesions / T1 CE lesions / cerebral atrophy) [R2 = 0.019, p= 0.513]
and CD133-deviation, however, a statistical trend was seen when
comparing EDSS-score with CD133 (R2 = 0.146, p = 0.059, see
Figure 5).
DISCUSSION
The present study for the first time systematically investigated
human CSF in inflammatory and degenerative diseases for
membrane particles carrying CD133. In essence, patients with
parkinsonism, normal pressure hydrocephalus as well as with
relapsing-remitting multiple sclerosis and SP multiple sclerosis
showed markedly increased CD133 levels. Several aspects emerge
from the data.
On a general note, analysis of membrane particles within
the human CSF – compared to solely protein-based CSF
investigation – may offer new approaches to study CNS diseases.
CD133-positive membrane particles occur in CSF most likely as
ectosomes, i.e., membrane particles derived from plasmalemma
notably membrane protrusions. Specific CNS cells, such as
ependymal cells and subventricular zone astrocytes which extend
their cilium into the lumen, represent a plausible source of
these CD133-positive membrane particles (Marzesco et al., 2005;
Dubreuil et al., 2007; Corbeil et al., 2009, 2013; Kriegstein and
Alvarez-Buylla, 2009). At the current stage of investigation, we
cannot rule out the contribution of infiltration cells in the CSF-
associated CD133 production. In this regard it has to be kept in
FIGURE 4 | Variation of membrane particle-associated CD133 in
neuroimmunological diseases. Variations of percentage of
CD133-deviation in patients with clinical isolated syndrome/relapsing remitting
multiple sclerosis (CIS/RRMS), secondary progressive multiple sclerosis
(SPMS), primary progressive multiple sclerosis (PPMS) and myelitis patients by
comparison to healthy adults are depicted in bar graph. Data are
mean ± SEM. N.s.: not significant.
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FIGURE 5 | Correlation of CD133 with clinical [Expanded Disability
Status Scale (EDSS)-score] and radiological findings (lesion score).
(A) Logistic regression model comparing the percentage of CD133-deviation
and EDSS score (R2 = 0.146; p = 0.059). (B) Logistic regression model
comparing the percentage of CD133-deviation and the radiological lesion
score (R2 = 0.019; p = 0.513).
mind that our study did not reveal a correlation between basic
CSF parameters like glucose, lactate, protein and CD133.
CD133 is also expressed by endothelial progenitor cells
(Peichev et al., 2000). The diseases analyzed in this study may
display processes of neovasculogenesis (Muramatsu et al., 2012)
and/or blood-brain barrier dysfunction (Stolp and Dziegielewska,
2009). The presence of CD133 in myelin should not be neglected
as well. Damage or remodeling of myelin sheaths might also
contribute to the release of CD133-positive membrane particles
by glia cells. In several diseases, a contribution of various
cellular types and processes might account for the elevation of
CD133 in CSF.
Given the fact that CD133 is associated to these CSF
membrane particles, it has important clinical implications of
a membrane particle-based CSF analysis for several reasons.
Astrocytes and especially their reduced astrocytic response have
been linked to neurodegenerative disease such as Alzheimer’s
disease and amyotrophic lateral sclerosis (Li et al., 2016). Results
suggest that astrocytes affect oligodendrocytes via Aß pathways
in Alzheimer’s disease, moreover, they are linked to progressive
loss of corticospinal and spinal motor neurons by progressive
reactive astrogliosis and reduction in myelin (Kang et al., 2013;
Fu et al., 2015; Li et al., 2016). As shown here, also Parkinson’s
disease patients show increased CSF-associated CD133. Though,
it remains speculative, if degeneration of myelinated axons from
the substantia nigra may contribute to elevated levels of myelin-
derived CD133. As patients in the different groups differ by
age, this raises the question of an additional influence of age
on membrane particle associated CD133. However, our previous
study demonstrated, that the concentration of CD133 is constant
over age and this fact could not account for elevated levels of
CD133 in several groups (Huttner et al., 2008).
Specifically interesting is the finding of increased CD133 in
multiple sclerosis, as CD133 was found in myelin sheaths of glial
cells (Corbeil et al., 2009). In multiple sclerosis, proinflammatory
cytokines are assumed to attack pathogenic cells and destroy
oligodendrocytes, myelin, and axons. Then protective trophic
factors may modify the blood-brain barrier and modulate the
extracellular matrix (Nait-Oumesmar et al., 2008; Guo et al.,
2011; Kummerfeld et al., 2012; Cristofanilli et al., 2014; Li et al.,
2016; Ludwin et al., 2016). Reactive gliogenesis on the one hand,
massive myelin destruction with the release of myelin-derived
CD133 into CSF on the other hand, may explain the high
CD133-levels in multiple sclerosis, especially in those patients
with a very high disease activity. It remains to be determined
whether the inflammation process itself stimulates the release of
CD133 and/or activates its expression. Interestingly, our analysis
demonstrated a statistical trend for an elevation of CD133 in
higher EDSS-scores. A relation between the inflammation and
CD133 expression was noted in solid cancers (Karbanová et al.,
2014; Rappa et al., 2015). Altogether, CD133 may serve as a
surrogate marker for monitoring disease activity – similar to
radiological findings – after initiation of immunomodulatory
therapy (Harris and Sadiq, 2014; Khan et al., 2016; Uher et al.,
2016; Zivadinov et al., 2016).
There are some shortcomings of the present study, notably
the lack of repeated CSF analyses for longitudinal CD133
assessment. Moreover, findings would be more robust if they
are replicated in a larger cohort of independent patients. Yet,
results may have been biased by analysis of semi-quantitative
immunoblotting, instead of ELISA or stronger methodological
approaches, leaving room for some technical uncertainty and
reliability. Finally, to determine the exact cellular source(s) of
the membrane particles and their origin (plasma membrane
versus multivesicular bodies), we would need an exhaustive
characterization (e.g., proteomics and/or lipidomics) of CD133-
positive membrane particles isolated from each patient group
(Redzic et al., 2014). These additional lines of investigation can
extend our observation to other biomarkers, e.g., non-coding
RNAs, and reveal discrete differences in the composition of
membrane particles in various neurological disease (Tietje et al.,
2014). So far, it remains unclear, if the isolated membrane
particles are solely ectosomes or mixture of them with exosomes.
Labeling for exosomal markers in future studies may solve this
issue. Taken together, our results not only indicate a possible
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clinical value (e.g., biomarker for monitoring of several diseases),
but also emphasize the need for further studies addressing all
these shortcomings.
CONCLUSION
Our study revealed elevated levels of membrane particle-
associated CD133 in patients with normal pressure
hydrocephalus, parkinsonism, relapsing-remitting and
secondary-progressive multiple sclerosis. Thus, CD133 may be
of clinical value for several neurological diseases.
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